title: Effect of PCI on quality of life in patients with stable coronary disease.
abstract: BACKGROUND
  It has not been clearly established whether percutaneous coronary intervention (PCI) can provide an incremental benefit in quality of life over that provided by optimal medical therapy among patients with chronic coronary artery disease.
  
  
  METHODS
  We randomly assigned 2287 patients with stable coronary disease to PCI plus optimal medical therapy or to optimal medical therapy alone. We assessed angina-specific health status (with the use of the Seattle Angina Questionnaire) and overall physical and mental function (with the use of the RAND 36-item health survey [RAND-36]).
  
  
  RESULTS
  At baseline, 22% of the patients were free of angina. At 3 months, 53% of the patients in the PCI group and 42% in the medical-therapy group were angina-free (P<0.001). Baseline mean (+/-SD) Seattle Angina Questionnaire scores (which range from 0 to 100, with higher scores indicating better health status) were 66+/-25 for physical limitations, 54+/-32 for angina stability, 69+/-26 for angina frequency, 87+/-16 for treatment satisfaction, and 51+/-25 for quality of life. By 3 months, these scores had increased in the PCI group, as compared with the medical-therapy group, to 76+/-24 versus 72+/-23 for physical limitation (P=0.004), 77+/-28 versus 73+/-27 for angina stability (P=0.002), 85+/-22 versus 80+/-23 for angina frequency (P<0.001), 92+/-12 versus 90+/-14 for treatment satisfaction (P<0.001), and 73+/-22 versus 68+/-23 for quality of life (P<0.001). In general, patients had an incremental benefit from PCI for 6 to 24 months; patients with more severe angina had a greater benefit from PCI. Similar incremental benefits from PCI were seen in some but not all RAND-36 domains. By 36 months, there was no significant difference in health status between the treatment groups.
  
  
  CONCLUSIONS
  Among patients with stable angina, both those treated with PCI and those treated with optimal medical therapy alone had marked improvements in health status during follow-up. The PCI group had small, but significant, incremental benefits that disappeared by 36 months. (ClinicalTrials.gov number, NCT00007657.)
authors.affiliation: Christiana Care Health System, Newark, DE 19718, USA. wweintraub@christianacare.org
authors.forename: William S
authors.initials: WS
authors.lastname: Weintraub
authors.forename: John A
authors.initials: JA
authors.lastname: Spertus
authors.forename: Paul
authors.initials: P
authors.lastname: Kolm
authors.forename: David J
authors.initials: DJ
authors.lastname: Maron
authors.forename: Zefeng
authors.initials: Z
authors.lastname: Zhang
authors.forename: Claudine
authors.initials: C
authors.lastname: Jurkovitz
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Pamela M
authors.initials: PM
authors.lastname: Hartigan
authors.forename: Cheryl
authors.initials: C
authors.lastname: Lewis
authors.forename: Emir
authors.initials: E
authors.lastname: Veledar
authors.forename: Jim
authors.initials: J
authors.lastname: Bowen
authors.forename: Sandra B
authors.initials: SB
authors.lastname: Dunbar
authors.forename: Christi
authors.initials: C
authors.lastname: Deaton
authors.forename: Stanley
authors.initials: S
authors.lastname: Kaufman
authors.forename: Robert A
authors.initials: RA
authors.lastname: O'Rourke
authors.forename: Ron
authors.initials: R
authors.lastname: Goeree
authors.forename: Paul G
authors.initials: PG
authors.lastname: Barnett
authors.forename: Koon K
authors.initials: KK
authors.lastname: Teo
authors.forename: William E
authors.initials: WE
authors.lastname: Boden
authors.forename: G B J
authors.initials: GB
authors.lastname: Mancini
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D017311:Amlodipine / Q000627:therapeutic use; D000787:Angina Pectoris / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D000077144:Clopidogrel; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000150:complications / Q000628:therapy; D018592:Cross-Over Studies; D004359:Drug Therapy, Combination; D005260:Female; D006304:Health Status; D006801:Humans; D007548:Isosorbide Dinitrate / Q000627:therapeutic use; D008297:Male; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D017060:Patient Satisfaction; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011788:Quality of Life; D015607:Stents; D011795:Surveys and Questionnaires; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D014665:Vasodilator Agents / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D017311:Amlodipine; D000077144:Clopidogrel; D008790:Metoprolol; D007548:Isosorbide Dinitrate; D013988:Ticlopidine; D001241:Aspirin